fosinopril

Fosinopril, a phosphinic acid-containing angiotensin-converting enzyme inhibitor, is effective in hypertension treatment. Fosinopril is a prodrug that is converted to its active metabolite fosinoprilat.

Fosinopril sodium is a phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.

Fosinopril-d7 is intended for use as an internal standard for the quantification of fosinopril by GC- or LC-MS. Fosinopril is a prodrug form of the angiotensin-converting enzyme inhibitor fosinoprilat. Oral administration of fosinopril inhibits angiotensin I-induced pressor responses in normotensive rats, dogs, and monkeys when administered at doses of 15, 15, and 10 µmol kg, respectively. Fosinopril reduces fractional shortening and decreases left ventricular size in a porcine model of congestive heart failure. Formulations containing fosinopril have been used in the treatment of hypertension and congestive heart failure.

Fosfenopril (Fosinoprilat) is a potent angiotensin-converting enzyme (ACE) inhibitor that mitigates lipopolysaccharide-induced inflammation in monocytes through the suppression of TLR4/NF-κB signaling pathways, and Fosfenopril is utilized in cardiovascular and anti-inflammatory research to investigate molecular mechanisms of ACE inhibition.

JBIR-22 is a natural inhibitor for protein−protein interaction of the homodimer of proteasome assembly factor 3.